A detailed history of Rhenman & Partners Asset Management Ab transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 1,975,000 shares of ESPR stock, worth $4.33 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
1,975,000
Previous 1,975,000 -0.0%
Holding current value
$4.33 Million
Previous $4.38 Million 25.68%
% of portfolio
0.27%
Previous 0.43%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.84 - $3.24 $3.63 Million - $6.4 Million
1,975,000 New
1,975,000 $4.38 Million
Q2 2022

Aug 12, 2022

SELL
$4.77 - $6.67 $389,146 - $544,151
-81,582 Reduced 8.31%
900,000 $5.72 Million
Q1 2022

May 13, 2022

SELL
$3.34 - $5.56 $61,516 - $102,404
-18,418 Reduced 1.84%
981,582 $4.56 Million
Q4 2021

Feb 11, 2022

BUY
$4.81 - $11.92 $1.82 Million - $4.5 Million
377,733 Added 60.7%
1,000,000 $4.96 Million
Q3 2021

Nov 12, 2021

BUY
$11.34 - $21.37 $567,000 - $1.07 Million
50,000 Added 8.74%
622,267 $7.5 Million
Q2 2021

Aug 13, 2021

SELL
$19.4 - $28.71 $387,185 - $572,994
-19,958 Reduced 3.37%
572,267 $12.1 Million
Q4 2020

Jan 19, 2021

BUY
$24.2 - $35.76 $3.32 Million - $4.91 Million
137,225 Added 30.16%
592,225 $15.4 Million
Q3 2020

Oct 13, 2020

BUY
$31.18 - $52.71 $935,400 - $1.58 Million
30,000 Added 7.06%
455,000 $16.9 Million
Q2 2020

Jul 16, 2020

SELL
$30.04 - $51.31 $5.04 Million - $8.61 Million
-167,798 Reduced 28.31%
425,000 $21.8 Million
Q1 2020

Apr 16, 2020

SELL
$27.44 - $73.84 $1.84 Million - $4.96 Million
-67,202 Reduced 10.18%
592,798 $18.7 Million
Q4 2019

Jan 17, 2020

BUY
$35.4 - $59.82 $146,768 - $248,013
4,146 Added 0.63%
660,000 $39.4 Million
Q3 2019

Oct 16, 2019

BUY
$34.47 - $47.53 $8.4 Million - $11.6 Million
243,761 Added 59.15%
655,854 $24 Million
Q2 2019

Jul 22, 2019

SELL
$40.1 - $52.33 $2.71 Million - $3.54 Million
-67,674 Reduced 14.11%
412,093 $19.2 Million
Q1 2019

Apr 11, 2019

BUY
$40.11 - $53.57 $5.05 Million - $6.74 Million
125,806 Added 35.54%
479,767 $19.3 Million
Q3 2018

Oct 03, 2018

SELL
$40.74 - $51.41 $2.13 Million - $2.69 Million
-52,400 Reduced 12.89%
353,961 $15.7 Million
Q2 2018

Jul 20, 2018

BUY
$36.2 - $76.4 $5.86 Million - $12.4 Million
161,821 Added 66.17%
406,361 $15.9 Million
Q1 2018

Apr 11, 2018

SELL
$65.94 - $80.76 $9.37 Million - $11.5 Million
-142,086 Reduced 36.75%
244,540 $17.7 Million
Q4 2017

Jan 19, 2018

BUY
$43.47 - $67.43 $3.25 Million - $5.05 Million
74,823 Added 24.0%
386,626 $25.5 Million
Q3 2017

Oct 13, 2017

BUY
$43.8 - $52.77 $13.7 Million - $16.5 Million
311,803
311,803 $15.6 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $146M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.